Formulary Watch |

Given together, bamlanivimab and etesevimab have an emergency use authorization from the FDA to both treat COVID-19 and prevent infection in those who have been exposed.

Livmarli is the first drug approved for Alagille syndrome.

Effective Oct. 1, 2021, Aetna has added several cancer drugs to its formulary and has updated exclusions and nonpreferred products.

Comprehensive medication management aided by AI clinical decision support can result in a large return on investment in a high-risk population. In this study, every dollar that was invested resulted in $12 in savings or cost avoidance.

Data is being presented at the 10th Annual IDWeek Virtual Conference, September 29 to October 3.

The companies are seeking accelerated approval based on the surrogate end point of beta amyloid reduction.

The flu program is the first in programs leveraging BioNTech’s mRNA technology for vaccines for other respiratory viruses, oncology, and genetic diseases.

Effective Jan. 1 2022, the move brings the price to 2008 levels.

Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.

Keytruda plus chemotherapy reduces the risk of death by 27% in patients with triple-negative breast cancer.

People over the age 65 and those at high risk of severe COVID-19, including health care workers and those with occupational exposure, are eligible for the booster.